Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.
2.

Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) to select the optimal patients for matched therapy?

Chae YK, Arya A, Chiec L, Shah H, Rosenberg A, Patel S, Raparia K, Choi J, Wainwright DA, Villaflor V, Cristofanilli M, Giles F.

Oncotarget. 2017 Aug 1;8(59):100863-100898. doi: 10.18632/oncotarget.19809. eCollection 2017 Nov 21. Review.

3.

The Utilization of Karyotyping, iFISH, and MLPA for the Detection of Recurrence Genetic Aberrations in Multiple Myeloma

Sommaluan S, Rerkamnuaychoke B, Pauwilai T, Chancharunee S, Onsod P, Pornsarayuth P, Chareonsirisuthigul T, Tammachote R, Siriboonpiputtana T.

Asian Pac J Cancer Prev. 2017 Nov 26;18(11):3135-3142.

4.

miR-511 promotes the proliferation of human hepatoma cells by targeting the 3'UTR of B cell translocation gene 1 (BTG1) mRNA.

Zhang SQ, Yang Z, Cai XL, Zhao M, Sun MM, Li J, Feng GX, Feng JY, Ye LH, Niu JQ, Zhang XD.

Acta Pharmacol Sin. 2017 Aug;38(8):1161-1170. doi: 10.1038/aps.2017.62. Epub 2017 Jun 12.

PMID:
28603285
5.

Elucidation of a four-site allosteric network in fibroblast growth factor receptor tyrosine kinases.

Chen H, Marsiglia WM, Cho MK, Huang Z, Deng J, Blais SP, Gai W, Bhattacharya S, Neubert TA, Traaseth NJ, Mohammadi M.

Elife. 2017 Feb 6;6. pii: e21137. doi: 10.7554/eLife.21137.

6.

Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application.

Chae YK, Ranganath K, Hammerman PS, Vaklavas C, Mohindra N, Kalyan A, Matsangou M, Costa R, Carneiro B, Villaflor VM, Cristofanilli M, Giles FJ.

Oncotarget. 2017 Feb 28;8(9):16052-16074. doi: 10.18632/oncotarget.14109. Review.

7.

Achondroplasia: Development, pathogenesis, and therapy.

Ornitz DM, Legeai-Mallet L.

Dev Dyn. 2017 Apr;246(4):291-309. doi: 10.1002/dvdy.24479. Epub 2017 Mar 2. Review.

8.

Genome-wide haplotype association study identify the FGFR2 gene as a risk gene for acute myeloid leukemia.

Lv H, Zhang M, Shang Z, Li J, Zhang S, Lian D, Zhang R.

Oncotarget. 2017 Jan 31;8(5):7891-7899. doi: 10.18632/oncotarget.13631.

9.

FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia.

Traer E, Martinez J, Javidi-Sharifi N, Agarwal A, Dunlap J, English I, Kovacsovics T, Tyner JW, Wong M, Druker BJ.

Cancer Res. 2016 Nov 15;76(22):6471-6482. doi: 10.1158/0008-5472.CAN-15-3569. Epub 2016 Sep 26.

10.

A small peptide promotes EphA2 kinase-dependent signaling by stabilizing EphA2 dimers.

Singh DR, Pasquale EB, Hristova K.

Biochim Biophys Acta. 2016 Sep;1860(9):1922-8. doi: 10.1016/j.bbagen.2016.06.004. Epub 2016 Jun 6.

11.

Rare SNPs in receptor tyrosine kinases are negative outcome predictors in multiple myeloma.

Keppler S, Weiβbach S, Langer C, Knop S, Pischimarov J, Kull M, Stühmer T, Steinbrunn T, Bargou R, Einsele H, Rosenwald A, Leich E.

Oncotarget. 2016 Jun 21;7(25):38762-38774. doi: 10.18632/oncotarget.9607.

12.

Expression of fibroblast growth factor receptor family members is associated with prognosis in early stage cervical cancer patients.

Choi CH, Chung JY, Kim JH, Kim BG, Hewitt SM.

J Transl Med. 2016 May 6;14(1):124. doi: 10.1186/s12967-016-0874-0.

13.

Immunoglobulin gene translocations in chronic lymphocytic leukemia: A report of 35 patients and review of the literature.

DE Braekeleer M, Tous C, Guéganic N, LE Bris MJ, Basinko A, Morel F, Douet-Guilbert N.

Mol Clin Oncol. 2016 May;4(5):682-694. Epub 2016 Feb 26.

14.

Effect of the achondroplasia mutation on FGFR3 dimerization and FGFR3 structural response to fgf1 and fgf2: A quantitative FRET study in osmotically derived plasma membrane vesicles.

Sarabipour S, Hristova K.

Biochim Biophys Acta. 2016 Jul;1858(7 Pt A):1436-42. doi: 10.1016/j.bbamem.2016.03.027. Epub 2016 Mar 31.

15.

Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use.

Patani H, Bunney TD, Thiyagarajan N, Norman RA, Ogg D, Breed J, Ashford P, Potterton A, Edwards M, Williams SV, Thomson GS, Pang CS, Knowles MA, Breeze AL, Orengo C, Phillips C, Katan M.

Oncotarget. 2016 Apr 26;7(17):24252-68. doi: 10.18632/oncotarget.8132.

16.

Gene integrated set profile analysis: a context-based approach for inferring biological endpoints.

Kowalski J, Dwivedi B, Newman S, Switchenko JM, Pauly R, Gutman DA, Arora J, Gandhi K, Ainslie K, Doho G, Qin Z, Moreno CS, Rossi MR, Vertino PM, Lonial S, Bernal-Mizrachi L, Boise LH.

Nucleic Acids Res. 2016 Apr 20;44(7):e69. doi: 10.1093/nar/gkv1503. Epub 2016 Jan 29.

17.

Nuclear translocation of fibroblast growth factor receptor 3 and its significance in pancreatic cancer.

Zhou L, Yao LT, Liang ZY, Zhou WX, You L, Shao QQ, Huang S, Guo JC, Zhao YP.

Int J Clin Exp Pathol. 2015 Nov 1;8(11):14640-8. eCollection 2015.

18.

Mechanism of FGF receptor dimerization and activation.

Sarabipour S, Hristova K.

Nat Commun. 2016 Jan 4;7:10262. doi: 10.1038/ncomms10262.

19.

Mechanisms and Clinical Applications of Genome Instability in Multiple Myeloma.

Cagnetta A, Lovera D, Grasso R, Colombo N, Canepa L, Ballerini F, Calvio M, Miglino M, Gobbi M, Lemoli R, Cea M.

Biomed Res Int. 2015;2015:943096. doi: 10.1155/2015/943096. Epub 2015 Oct 22. Review.

20.

Association of FGFR3 and FGFR4 gene polymorphisms with breast cancer in Chinese women of Heilongjiang province.

Jiang Y, Sun S, Wei W, Ren Y, Liu J, Pang D.

Oncotarget. 2015 Oct 20;6(32):34023-9. doi: 10.18632/oncotarget.5850.

Supplemental Content

Support Center